Gouveia Emanuel, de Sousa Rita Teixeira, Aguiar Sandra I, Gírio Ana, Costa Inês, Dionísio Maria Rita, Moital Inês
Department of Medical Oncology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
Department of Medical Oncology, Centro Hospitalar Universitário Lisboa Norte-Hospital de Santa Maria, Lisbon, Portugal.
Clin Transl Oncol. 2025 Feb;27(2):770-777. doi: 10.1007/s12094-024-03579-1. Epub 2024 Jul 16.
Malignant melanoma is an aggressive cancer, and there is a notable dearth on epidemiology, clinical and treatment characterization within the Portuguese population. We performed a scoping review to identify real-world evidence studies focused in Portuguese adult patients with malignant melanoma.
A comprehensive search was conducted. After screening, we described the studies by design, sample size, geographics, setting, population, and outcomes reported.
The search yielded 54 studies, mainly retrospective (79.6%). The population assessed was heterogeneous varying from patients with melanoma in general to specific types of melanoma, or even more restricted to patients with specific conditions. The evidence found was mostly concerning clinical outcomes (n=46), patients' clinical profile (n=44) and demographic characterization (n=48). Treatment information was described in 30 studies whereas only 18 reported epidemiological parameters. Studies were mainly performed by the major oncology centers in Lisbon, Oporto and Coimbra, and only two evaluated the entire Portuguese population. To allow comparability, only studies including patients with cutaneous malignant melanoma were considered (13 of the 54) for outcomes evaluation analysis. Median OS varied from 18 to 36 months, assessed after melanoma treatment. Incidence was the most reported epidemiological parameter, confirming the increasing number of cutaneous malignant melanoma patients over the years. Only one study reported prevalence and four reported mortality rates.
The evidence found confirms the lack of information about malignant melanoma in Portugal, highlighting the need of real-world studies to assess melanoma prevalence and incidence rates, current treatment approaches, and clinical characterization of these patients.
恶性黑色素瘤是一种侵袭性癌症，葡萄牙人群在流行病学、临床及治疗特征方面存在明显不足。我们进行了一项范围综述，以确定聚焦于葡萄牙成年恶性黑色素瘤患者的真实世界证据研究。
进行了全面检索。筛选后，我们按设计、样本量、地理位置、研究背景、人群及报告的结果对研究进行了描述。
检索得到54项研究，主要为回顾性研究（79.6%）。评估的人群具有异质性，从一般黑色素瘤患者到特定类型的黑色素瘤患者，甚至更局限于有特定病情的患者。所发现的证据大多涉及临床结果（n = 46）、患者临床特征（n = 44）和人口统计学特征（n = 48）。30项研究描述了治疗信息，而仅有18项报告了流行病学参数。研究主要由里斯本、波尔图和科英布拉的主要肿瘤中心开展，仅有两项评估了整个葡萄牙人群。为便于比较，仅将包括皮肤恶性黑色素瘤患者的研究（54项中的13项）纳入结果评估分析。黑色素瘤治疗后评估的总生存期（OS）中位数为18至36个月。发病率是报告最多的流行病学参数，证实了这些年皮肤恶性黑色素瘤患者数量的增加。仅有一项研究报告了患病率，四项报告了死亡率。
所发现的证据证实了葡萄牙在恶性黑色素瘤方面信息的匮乏，凸显了开展真实世界研究以评估黑色素瘤患病率和发病率、当前治疗方法以及这些患者临床特征的必要性。
